[Effects of proteasome inhibitor bortezomib on NF-kappaB activity and ICAM-1 mRNA expression of K562 cells].
This study was aimed to investigate the effects of proteasome inhibitor bortezomib (Velcade, PS-341) on the activation of NF-kappaB and the expression of intercellular adhesion molecule-1 (ICAM-1) in K562 cells. The K562 cells were incubated in the culture of RPMI 1640 with 10% calf serum in 12-well plates and exposed to 0, 10, 20, 30, 50 and 100 nmol/L of bortezomib for 6 hours. The activation of NF-kappaB was analyzed by SP immunohistochemistry, meanwhile RT-PCR was performed to detect expression of ICAM-1. The results showed that the activation of NF-kappaB and the expression of ICAM-1 in K562 cells decreased significantly after bortezomib treatment. The inhibitory effect on ICAM-1 was probably related with the activity suppression of NF-kappaB. It is concluded that proteasome inhibitor bortezomib downregulates the expression of K562 cell ICAM-1 by inhibiting the activity of NF-kappaB, which provides a new way for the target therapy in acute leukemia.
Lu
Shi-Feng
SF
Department of Hematology, The First Hospital, Nanjing Medical University, Nanjing 210029, Jiangsu Province, China.
Lu
Hua
H
Shen
Wen-Yi
WY
Zhang
Jian-Fu
JF
Liu
Peng
P
Wang
Yong-Ren
YR
Wang
Li-Xia
LX
Yang
Hui
H
Li
Jian-Yong
JY
D001897:Boronic Acids / Q000494:pharmacology*; D000069286:Bortezomib; D006801:Humans; D018799:Intercellular Adhesion Molecule-1 / Q000378:metabolism*; D020014:K562 Cells; D016328:NF-kappa B / Q000378:metabolism*; D011480:Protease Inhibitors / Q000494:pharmacology*; D011719:Pyrazines / Q000494:pharmacology*
D001897:Boronic Acids; D016328:NF-kappa B; D011480:Protease Inhibitors; D011719:Pyrazines; D018799:Intercellular Adhesion Molecule-1; D000069286:Bortezomib